E Squared Capital Management
VC Fund
New York, United States
E Squared Capital Management is a multi-strategy fund that invests in public and private companies. Founded in 2009, our flexible approach and team of seasoned professionals has particular expertise investing in companies that will provide for superior risk-adjusted returns with low correlation to overall markets in a wide array of industries.We achieve this objective by strategically investing in equity securities. Our proprietary analysis uncovers companies that are undervalued when compared to our internally generated price targets. We often invest in special events including restructurings, spin-offs, IPOs, secondary offerings, block trades, and registered direct offerings. E Squared will seek to capture the relative value inherent in equity issues, taking a number of fundamental and trading factors into consideration.
- Total investments:
- 17
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries E Squared Capital Management invests in
Stages E Squared Capital Management invests in
Countries E Squared Capital Management invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Ed Ilyadzhanov
|
|||
Les Funtleyder
|
|||
Investment Focus
Industry
- Health Care 5 (29%)
- Biotechnology 4 (24%)
- Medical 3 (18%)
- Software 3 (18%)
- Cannabis 2 (12%)
Stage
- Funding Round 7 (41%)
- Series A 3 (18%)
- Series B 3 (18%)
- Seed 2 (12%)
- Convertible Note 1 (6%)
Country
- United States 14 (82%)
- Canada 1 (6%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Ed Ilyadzhanov
Managing Principal
|
Managing Principal | Total investments: 0 | Find email | |
|
Les Funtleyder
Portfolio Manager- Healthcare
|
Portfolio Manager- Healthcare | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Valo Health
|
Valo Health, LLC (Valo) is a technology company that is using human-centric data and machine learning-anchored computation to transform the drug discovery and development process. By integrating data across the drug development lifecycle, the discovery and development of life-changing treatments can be accelerated, with the potential to reducecost, time, and failure rate. The company's Opal Computational Platform™, a fully integrated, componentized, end-to-end drug development platform, offers a unique approach to therapeutic development, that enables Valo to advance a robust pipeline of candidates across cardiovascular disease, oncology, and neurodegeneration. | $190M / Series B / Jan 11, 2021 | |
Picket pharmaceuticals
|
Picket Pharmaceuticals is a privately held company. It develops and brings to market innovative complex generic pharmaceutical products across a range of therapeutic areas. | Jan 01, 2021 | |
|
Picket pharmaceuticals
|
Picket Pharmaceuticals is a privately held company. It develops and brings to market innovative complex generic pharmaceutical products across a range of therapeutic areas. | Seed / Jan 01, 2021 | |
Nu Ride
|
Lordstown Motors is an automotive company that develops and manufactures light-duty electric trucks for sale to fleet customers. The company was founded in 2019 by Steve Burns and is headquartered in Lordstown, Ohio. | $10.1M / Venture - Series Unknown / Jul 06, 2020 | |
Radformation
|
Radformation helps cancer patients receive treatment faster with safer, smarter radiation treatment plans. Radformation specializes in radiation therapy workflow automation.Their solutions will save you time, eliminate planning errors, and enable you to design the optimal treatment for your patients. Their founders were physicists in cancercenters when they identified issues of the time-consuming, error-prone treatment planning workflow. | Seed / Oct 09, 2019 | |
Applied Therapeutics
|
Applied Therapeutics operates as a biotechnology company. The company focuses on developing transformative drugs in areas of high unmet medical need -fatal and debilitating diseases for which no therapies are approved. The company is developing a pipeline of novel product candidates against previously validated and well-known molecular targets. Ituses technological advances and abbreviated regulatory pathways, wherever possible, to design drugs for indications of significant unmet medical needs. | $25M / Series B / Feb 01, 2019 | |
Stimwave Technologies
|
Stimwave Technologies, Inc., a medical device company, engages in the development, manufacture, commercialization, and marketing of wireless microsize injectable medical devices for neurology markets. The company was formerly known as Neural Micro Incorporated. Stimwave Technologies, Inc. was incorporated in 2010 and is based in Scottsdale,Arizona. | $60M / Jul 25, 2018 | |
JUUL
|
JUUL is an electronics company that specializes in improving alternatives for adult smokers and has launched a nicotine vaporizer in US. The company is a simply satisfying alternative for adult smokers. JUUL Labs’ mission is to eliminate combustible cigarettes. The company was founded to provide the 1 billion smokers worldwide a true alternativeto cigarettes that enables them to permanently switch. Its research indicates hundreds of thousands of smokers have already switched to JUUL, and they are working to enable millions more to switch in the coming years.The company is headquartered in San Francisco, California, United States. | $650M / Jul 10, 2018 | |
Twist Bioscience
|
Twist Bioscience is a biotechnology company that offers synthetic DNA solutions, gene synthesis, and variant libraries. It produces synthetic DNA used in applications across healthcare, agriculture, industrial chemicals, and data storage. The company develops a silicon-based DNA synthesis platform to enable high-throughput, scalable, and preciseDNA production. Its technology supports research and development in drug discovery and specialty chemical production. | $50M / Apr 02, 2018 | |
EGenesis
|
EGenesis operates as a biotechnology company. The Company focuses on leveraging genome editing technology to deliver safe and effective human transplantable cells, tissues, and organs. eGenesis serves patients worldwide. | $38M / Series A / Mar 16, 2017 | |
| See all 17 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does E Squared Capital Management invest in?
E Squared Capital Management invests primarily in Health Care, Biotechnology and Medical startups, most often at Funding Round and Series A stage. Most of the 17 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact E Squared Capital Management?
Public channels for E Squared Capital Management include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at E Squared Capital Management?
The team at E Squared Capital Management includes Ed Ilyadzhanov (Managing Principal) and Les Funtleyder (Portfolio Manager- Healthcare). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
